


PHARMACEUTICAL 2019

## Esperion Therapeutics Inc. Rank 290 of 363





**ESPERION**<sup>®</sup>



PHARMACEUTICAL 2019

## **ESPERION**

## Esperion Therapeutics Inc. Rank 290 of 363

The relative strengths and weaknesses of Esperion Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Esperion Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 23% points. The greatest weakness of Esperion Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 112% points.

The company's Economic Capital Ratio, given in the ranking table, is -63%, being 100% points below the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	142,632
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	64,333
Liabilities, Non-Current	0
Other Assets	299
Other Compr. Net Income	526
Other Expenses	0
Other Liabilities	0
Other Net Income	2,775
Other Revenues	0
Property and Equipment	520
Research and Development	171,488
Selling, General and Administrative Expense	33,097

Output Variable	Value in 1000 USD
Assets	143,451
Liabilities	64,333
Expenses	204,585
Revenues	0
Stockholders Equity	79,118
Net Income	-201,810
Comprehensive Net Income	-201,547
Economic Capital Ratio	-63%

